Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the first 5 patients previously announced in Q1 2020 JENA, Germany, April 15, 2021 ...
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative ...
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohort Treatment was well tolerated; no dose-related adverse events observed Final ...
Darin hatten 13 Patienten mit Pyoderma gangraenosum (Dermatitis ulcerosa) randomisiert und doppelblind eine einmalige Infusion mit 5 mg/kg des TNF-alpha-Blockers Infliximab (Remicade®) erhalten. 17 ...
(RTTNews) - Shares of InflaRx N.V. (IFRX) have been on a roll since the beginning of this year, hitting new highs. Germany-based InflaRx is a clinical-stage biopharmaceutical company focused on ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Target enrollment of 18 patients reached across three different dose groups Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback